Return to search

Bitterman joins Atlas Venture

Atlas Venture said June 1 that Kevin Bitterman is joining the firm as a partner. Bitterman was previously a partner with Polaris Partners.


CAMBRIDGE, Mass.–(BUSINESS WIRE)–Atlas Venture, a leading early stage venture capital firm investing in promising biotech innovation, today announced that Kevin Bitterman is joining the firm’s team as a partner. Bitterman brings a wealth of experience and an accomplished record in startup creation and venture investing.

“I couldn’t be more thrilled to join Atlas at such an exciting time for the firm,” said Bitterman. “Atlas has a deep commitment to transforming medicine through groundbreaking science and a rich history of partnering with entrepreneurs at the earliest stages of company inception. I’m looking forward to contributing as the team builds the next generation of great biotech companies.”
“Kevin is an exceptional venture investor who brings proven company creation skills and deep scientific expertise to Atlas,” said David Grayzel, an Atlas partner. “We have known Kevin for years in the Boston biotech ecosystem and are delighted to welcome him to the team.” In addition to Grayzel, Bitterman joins Atlas partners Peter Barrett, Bruce Booth, Jean François Formela, and Jason Rhodes.
Bitterman joins Atlas after a successful tenure with Polaris Partners. Over the past decade, Bitterman was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra and co-founded Genocea Biosciences (NASDAQ: GNCA). He was also on the boards of directors of InSeal Medical, Kala Pharmaceuticals, Neuronetics, Taris Biomedical and Vets First Choice. He is active in the local life science ecosystem, serving on the Scientific Advisory Board of the Massachusetts Life Sciences Center (MLSC) and as Board Chair of the New England Venture Capital Association (NEVCA).
About Atlas Venture
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit